Antibe Analyst Call – Positive Phase IIB Dose-Ranging, Efficacy Results

June 4, 2020 | Conference Call

Antibe hosted a conference call to discuss the recent positive results of the Phase IIB dose-ranging, efficacy study for otenaproxesul (ATB-346). Management provided a brief summary of the results which was followed by a Q&A session for analysts. Please click on the “Read” link below to listen to an audio replay of the call.

Learn more See all events


This is an external link. Click “OK” to continue.